IsoRay, Inc.(NYSEMKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced it will host a booth at the Annual Meeting of the American Brachytherapy Society (ABS). The annual ABS meeting will take place April 9-11, 2015 in Orlando, Florida.
IsoRay CEO Dwight Babcock commented, “IsoRay is pleased to again participate at the ABS annual meeting. At this meeting, major institution representatives will speak about their experiences and success in treating aggressive cancers, as well as treatment planning methods, using IsoRay’s Cesium-131 isotope. They include the University of Pittsburg Medical Center (UPMC), Sidney Kimmel Medical College at Thomas Jefferson University, University of Kentucky and Tufts University School of Medicine. The four oral presentations at the annual meeting will present results indicating Cesium-131 is an effective treatment modality for incorporation into primary management of gynecologic cancers, demonstrate the lack of significant long-term rectal toxicity following Cesium-131 treatment, discuss the use of FMEA (failure mode effect analysis) to improve the quality of Cesium-131 treatment of head and neck cancer, and provide new insight into the physics associated with Cesium-131 as applied to permanent brain brachytherapy treatment planning . Our participation in many new body sites has IsoRay’s sales team meeting a new and growing mix of medical professionals. This was evidenced by our first participation in the Society of Gynecologic Oncology (SGO) conference two weeks ago, where Dr. Feddock gave a dinner presentation on Cesium-131. With our broader reach and our newly published study results, the medical community has become more aware of the innovative alternative our Cesium-131 products offer patients.”
IsoRay’s various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay’s cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life.
IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).
In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh. IsoRay also sells several new implantable devices, including the GliaSite® radiation therapy system. (Original Source)
Shares of IsoRay Inc closed today at $1.525, down $0.015 or 0.97%. ISR has a 1-year high of $3.29 and a 1-year low of $1.22. The stock’s 50-day moving average is $1.56 and it’s 200-day moving average is $1.56.
On the ratings front, Maxim Group analyst Jason Kolbert reiterated a Buy rating on ISR with a price target of $5, in a report issued on February 18. The current price target implies an upside of 226.8% from current levels,
According to TipRanks.com, Kolbert has a total average return of 12.0%, a 48.4% success rate, and is ranked #211 out of 3571 analysts.
IsoRay Inc offers solutions for the treatment and diagnosis of disease using medical isotopes.